AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06545851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy - constant oxygen flow
Description: During five exercise training sessions, oxygen therapy is delivered via prescribed constant oxygen flow
Study NCT06545851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy - automatic titrating oxygen flow
Description: During five exercise sessions, oxygen therapy is delivered via an automatically titrated oxygen flow rate to maintain an SpO2 target of 90-94%.
Study NCT05172206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: symptom-focused rehabilitation
Description: Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
Study NCT05309174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: USG-guided iSLN block
Description: Ultrasound-guided internal branch of the upper laryngeal nerve block (USG-guided iSLN block) bilaterally with 5 ml of 0.375% ropivacaine , before general anesthesia.
Study NCT04923269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3532226
Description: Administered SC.
Study NCT04923269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT05341076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotomy
Description: Amniotomy, artificial rupture of membranes, is done with an initial delay of labor (in partograph: extension beyond the alert line, in labor scale: when progress reaches the membrane line)
Study NCT05341076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy
Description: Amniotomy, artificial rupture of membranes, is done with an initial delay of labor (in partograph: extension beyond the alert line, in labor scale: when progress reaches the membrane line)
Study NCT05341076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)
Study NCT05341076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)
Study NCT05341076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean Section
Description: Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
Study NCT05341076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Section
Description: Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
Study NCT05301101 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Description: Patients will undergo re-irradiation following treatment planning based on current standard practice as determined by treating physicians and multidisciplinary teams.
Study NCT05398731 — intervention group
Intervention type: OTHER
Intervention: Covid_19
Description: Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19
Study NCT05870826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiwave locked system laser therapy
Description: High intensity laser therapy
Study NCT05870826 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham laser therapy
Description: Sham laser therapy
Study NCT04974645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: W-SUDs
Description: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
Study NCT04974645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digitally-delivered Psychoeducation
Description: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
Study NCT06260384 — intervention group
Intervention type: OTHER
Intervention: electrocardiogram
Description: it is a non-invasive study to diagnose criteria of Wolf-Parkinson-Wall syndrome and detect any arrhythmias
Study NCT01669278 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosheath
Description: Flexible sheathed nasopharyngolaryngoscopy
Study NCT04972071 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Knowledge translation (KT) of the CSRS based practice recommendations
Description: The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g., troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; and 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. All the components of the practice recommendations will be applied by the ED physician treating the patient.
Study NCT05371483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Ambulatory Blood Pressure Monitoring
Description: Arm blood pressure cuff that will automatically inflate every 15-30 minutes to check blood pressure while awake and asleep over 24 hours. Patient will also complete a sleep diary and wear an actigraphy watch during this test.
Study NCT05371483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oculo-Cognitive Addition Test (OCAT)
Description: Tracks users' eye movements as they complete a simple mental addition test.
Study NCT05172206 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
Study NCT04703972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinical assessment (mood relapses identification)
Description: clinical assessment via psychometric scales physiological data acquired automatically via the connected device (wristwatch, wristband)
Study NCT05461092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Pain Trajectory
Description: Questionnaire assessing pain location, severity, impact to quality of life, and medications used to alleviate.
Study NCT05461092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tampa Scale of Kinesiophobia
Description: Questionnaire assessing Kinesiophobia
Study NCT04720456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
Study NCT04720456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
Study NCT04720456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
Study NCT05706272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Description: The intervention includes a holistic comprehensive geriatric assessment using the PASTEL assessment tool that includes medical, psychiatric, functional and social aspects. Physical tests will include function, risk of falling, hand muscle strength, Timed up and Go (TUG), chair-stand test, blood pressure, saturation and BMI. A proactive person centered care plan will be established based on identified needs and the patients own priorities. A nurse will coordinate the care in the elderly team at the intervention practice with access to rehabilitation staff such as physiotherapist and occupational therapist. Follow-ups at the primary care practices will be carried out in accordance with the study plan. To strengthen care coordination, contact will be taken with other health care providers before the follow-ups.
Study NCT05706272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: The control group will receive care as usual at the matched control primary care centers
Study NCT05372601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relax+
Description: Prebiotics, daily administered
Study NCT05372601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo, daily administered
Study NCT05336240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Communication 2 Virtual (PCOM2-virtual)
Description: The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.
Study NCT05336240 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Communication Standard (PCOM-standard)
Description: The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
Study NCT06572566 — intervention group
Intervention type: OTHER
Intervention: Non-invasive examination and assessment.
Description: 1) Test the blood and urine components of all subjects to evaluate the damage to kidney function caused by excessive cadmium. 2) Conduct MRI examinations on all subjects to evaluate changes in brain functional connectivity, metabolism, and structure after excessive cadmium exposure. 3) Conduct bone density examinations on all subjects to evaluate changes in bone density after excessive cadmium exposure. (3) Clinical psychiatric assessment: All subjects will be assessed on their mental and psychological conditions such as pain, cognitive function, depression, anxiety, mania, sleep quality, and suicide risk.
Study NCT05173519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnibond Topical Skin Adhesive
Description: Application of Omnibond topical skin adhesive to close incision following surgery
Study NCT05173519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond Advanced Topical Skin Adhesive
Description: Application of Dermabond topical skin adhesive to close incision following surgery
Study NCT06058507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT angiography
Description: No intervention was made
Study NCT05928273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corheart 6 Left Ventricular Assist System
Description: Implantation of left ventricular assist device for hemodynamic support
Study NCT05695079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No cooling (control)
Description: Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7.
Study NCT05695079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric fan (low airflow)
Description: Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 2 m/s to the front of the body.
Study NCT06436976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-002 (Lactobacillus reuteri ATG-F4
Description: The group that will be consuming probiotics for 12 weeks.
Study NCT04907097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Monomeric and oligomeric flavanols
Description: Monomeric and oligomeric flavanols will be derived from Vitis vinifera seeds extract.
Study NCT04907097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo capsuled will be used as a comparator.
Study NCT05461092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tampa Scale of Kinesiophobia
Description: Questionnaire assessing Kinesiophobia
Study NCT05461092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Recovery 15
Description: Questionnaire assessing postoperative quality of recovery
Study NCT05461092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Recovery 15
Description: Questionnaire assessing postoperative quality of recovery
Study NCT05469737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Specified dose on specified days
Study NCT05469737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oral Azacitidine
Description: Specified dose on specified days
Study NCT05913752 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CMND-100
Description: The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class
Study NCT05913752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CMND-100
Description: The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class
Study NCT05632861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuHuangLianzonggan capsule
Description: HuHuangLianzonggan capsule, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
Study NCT05632861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HuHuangLianzonggan capsule placebo
Description: HuHuangLianzonggan capsule placebo, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
Study NCT00987818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin measurement
Description: Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
Study NCT00987818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Procalcitonin measurement
Description: Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
Study NCT05392842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corchorus Olitorius Buccal fast dissolving Films
Description: Corchorus Olitorius Buccal fast dissolving Films
Study NCT05392842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plain mucoadhesive fast dissolving film
Description: plain mucoadhesive fast dissolving film
Study NCT06545539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Preparedness Exercise Class
Description: The class will be held bi-weekly at two different locations. To ensure consistency across groups, the instructor(s) will adhere to a standardized class outline. Exercise modifications will be provided as necessary to adjust the intensity, ensuring all participants can follow the program.
Study NCT05730933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Subjects will receive a behavioral intervention with additional education in combination with more frequent follow up and patient reminders
Study NCT06456775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-SSM
Description: Tele-SSM an individual-level psychosocial intervention based on cognitive behavior therapy principles and non-violent communication. The intervention consists of the following 10 sessions delivered through 10 weekly coaching calls delivered by Zoom (audio only).
Study NCT05006287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulants (NOACs)
Description: NOAC Group (Intervention):~Patients randomized to the NOAC group will receive a NOAC dosed according to the Canadian monograph for the respective indication. Patients receiving a NOAC before cardiac surgery will resume the same NOAC as pre-operatively, whereas patients not previously receiving a NOAC will preferentially receive apixaban according to local practice. The NOAC will be started no earlier than post-operative day 5 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until the NOAC is initiated.
Study NCT05006287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin Group (Comparator):~Patients randomized to the warfarin group will receive warfarin titrated to achieve a target International Normalized Ratio (INR) of 2.5 (range 2.0 to 3.0). Warfarin will be started as early as post-operative day 1 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until INR is 2.0 or above.
Study NCT04797104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: 300 mg Q4W
Study NCT04797104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lerodalcibep
Description: 300 mg Q4W
Study NCT05211570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB8939
Description: Intravenous injection (from an initial dose of 0.9 mg/m²)
Study NCT05211570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous injection (75 mg/m²)
Study NCT04968730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative rehabilitation nursing
Description: Make postoperative rehabilitation plan according to nursing experience for group A Develop rehabilitation process according to the activity plan for group B
Study NCT04968730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation nursing
Description: Make postoperative rehabilitation plan according to nursing experience for group A Develop rehabilitation process according to the activity plan for group B
Study NCT04930289 — intervention group
Intervention type: DEVICE
Intervention: LungGuard
Description: The LUNGguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs. The intended organ storage time for the LUNGguard is up to 8 hours.
Study NCT04930289 — intervention group
Intervention type: DEVICE
Intervention: BAROGuard
Description: The BAROguard (the System) is ultraportable hypothermic preservation and transport system intended for use with donor lungs. BAROguard is a legally marketed, FDA cleared medical device in the United States. The intended organ storage time for BAROguard™ is up to 8 hours.